Real-time trafficking and signaling of the glucagon-like peptide-1 receptor

Nov 27, 2013Molecular and cellular endocrinology

Real-time movement and signaling of the glucagon-like peptide-1 receptor

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

The human GLP-1 receptor internalizes rapidly in response to GLP-1 and its analogues.

  • Internalization occurs with similar speed for GLP-1, exendin-4, and liraglutide.
  • Receptor internalization was confirmed in mouse pancreatic islets.
  • GLP-1 receptor recycles faster when activated by GLP-1 compared to its analogues.
  • A prolonged cycling of ligand-activated GLP-1 receptors is linked to extended cAMP signaling.

AI simplified

Full Text

Full text is available at the source.
View full text (XML) ↗View full text ↗

Related papers

Jun '11
Glucagon-like peptide-1 boosts cell signals and slows breast cancer cell growth
top 10% journal
cited by 98 papers
research support, non-u.s. gov't
Dec '14
How interactions and movement of glucagon-like peptide-1 receptors affect their function
top 10% journal
cited by 75 papers
research support, non-u.s. gov't
May '14
Activating a hormone receptor slows growth and causes death of human pancreatic cancer cells through a cAMP-related process
top 10% journal
cited by 62 papers
research support, non-u.s. gov't
Sep '12
Stimulating GLP-1 receptors or blocking DPP-4 does not speed up tumor growth in mice exposed to cancer-causing chemicals
cited by 89 papers
research support, non-u.s. gov't
Jul '07
Glucagon-like peptide-1 and its activator exendin-4 influence bile duct cell responses to bile flow blockage
top 1% journal
cited by 85 papers
research support, n.i.h., extramural
May '10
Active GLP-1 receptor in bone-forming cells that works separately from the usual cAMP-linked receptor
cited by 127 papers
research support, non-u.s. gov't
Jul '11
Activating a hormone receptor slows growth and increases cell death in mouse colon cancer cells
top 10% journal
cited by 117 papers
research support, non-u.s. gov't

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #36
Tirzepatide beats semaglutide for weight loss: 8.2% vs 5.8% body weight reduction at 12 months
1 week ago7 studies
issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
2 weeks ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
3 weeks ago7 studies
issue #33
Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes
4 weeks ago7 studies
issue #32
60% of weight lost on GLP-1 drugs returns within a year of stopping
5 weeks ago7 studies
issue #31
Semaglutide linked to 54% lower risk of new sleep apnea cases in 1.25 million patients
6 weeks ago7 studies
issue #30
Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity
7 weeks ago7 studies
issue #29
Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%
8 weeks ago7 studies
issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
9 weeks ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
10 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief